Dahlia Medical Communications

Month: April 2024

  • Vadadustat Essentials for Healthcare Professionals

    —

    by

    Rachael Hills
    in

    What is vadadustat?1 The FDA approved vadadustat (Vafseo®) in March 2024 for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is only approved for dialysis dependent CKD patients. It is not indicated to replace blood transfusions. What is vadadustat’s mechanism of action? Vadadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF PF) inhibitor.…

  • Vadadustat Basics for Patients

    —

    by

    Rachael Hills
    in

    Disclaimer: Patients should review this guide before discussing vadadustat with their healthcare provider. Patients should always discuss potential medication changes and additions with their healthcare provider. What is vadadustat? Vadadustat (Vafseo®) is a new drug from Akebia Therapeutics, Inc. The FDA approved it for the treatment of anemia caused by chronic kidney disease (CKD).1 Vadadustat…

  • Fezolinetant Essentials for Healthcare Professionals

    —

    by

    Rachael Hills
    in

    Fezolinetant Basics for Patients is available at this link: Fezolinetant Basics for Patients. What is fezolinetant (VeozahTM) and its mechanism of action? Fezolinetant is a neurokinin-3 receptor antagonist.1 The FDA approved it for treating menopausal vasomotor symptoms (aka hot flashes). The antagonism blocks neurokinin B from acting in the brain’s thermoregulatory center.1 This decreases hot…

  • Fezolinetant Basics for Patients

    —

    by

    Rachael Hills
    in

    Fezolinetant is an FDA-approved drug for treating hot flashes.1 Astellas Pharma sells it under the brand name VeozahTM. Fezolinetant reduces the number of hot flashes experienced during menopause.1 Traditionally, physicians prescribe hormone replacement therapy (HRT) to treat hot flashes. The historic alternative to HRT is SSRIs (drugs used to treat depression and anxiety).2 Patients should…